Tech Company Financing Transactions

Agios Pharmaceuticals Funding Round

Agios Pharmaceuticals, operating out of Cambridge, received $78 million in funding from Arch Venture Partners, Celgene and Flagship Pioneering.

Transaction Overview

Company Name
Agios Pharmaceuticals
Announced On
11/17/2011
Transaction Type
Venture Equity
Amount
$78,000,000
Round
Series C
Investors

Arch Venture Partners (Robert Nelson)

Celgene (Perry Karsen)

Flagship Pioneering (Douglas Cole)

Third Rock Ventures (Kevin Starr)

Proceeds Purpose
The proceeds of this financing will be used to advance the company's rapidly emerging portfolio of cancer metabolism therapeutics into the clinic and to expand research and development into inborn errors of metabolism (IEMs), a group of genetic disorders with high unmet medical need.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
88 Sidney St.
Cambridge, MA 02139
USA
Phone
(617) 649-8600
Website
www.agios.com
Email Address
[email protected]
Overview
Agios (NASDAQ: AGIO) is a biopharmaceutical company at the forefront of one of the most exciting new areas of cancer research: cancer metabolism. Cancer metabolism represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth.
Profile
Agios Pharmaceuticals LinkedIn Company Profile
Social Media
Agios Pharmaceuticals Company Twitter Account
Company News
Agios Pharmaceuticals News
Facebook
Agios Pharmaceuticals on Facebook
YouTube
Agios Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jacqualyn Fouse
  Jacqualyn Fouse LinkedIn Profile  Jacqualyn Fouse Twitter Account  Jacqualyn Fouse News  Jacqualyn Fouse on Facebook
Chief Financial Officer
Andrew Hirsch
  Andrew Hirsch LinkedIn Profile  Andrew Hirsch Twitter Account  Andrew Hirsch News  Andrew Hirsch on Facebook
Chief Medical Officer
Chris Bowden
  Chris Bowden LinkedIn Profile  Chris Bowden Twitter Account  Chris Bowden News  Chris Bowden on Facebook
Chief Scientific Officer
Scott Biller
  Scott Biller LinkedIn Profile  Scott Biller Twitter Account  Scott Biller News  Scott Biller on Facebook
VP - Human Resources
Melissa McLaughlin
  Melissa McLaughlin LinkedIn Profile  Melissa McLaughlin Twitter Account  Melissa McLaughlin News  Melissa McLaughlin on Facebook
VP - Marketing
Darrin Miles
  Darrin Miles LinkedIn Profile  Darrin Miles Twitter Account  Darrin Miles News  Darrin Miles on Facebook
VP - Operations
Clive Patience
  Clive Patience LinkedIn Profile  Clive Patience Twitter Account  Clive Patience News  Clive Patience on Facebook

 

 

Browse more venture capital transactions:

Prev: 11/17/2011: Impermium venture capital transaction
Next: 11/18/2011: UserVoice venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.